Meanwhile, the development of a new generation of antibody-drug conjugated targeting HER2, that showed activity in patients with HER2-low breast cancer (which is defined as HER2 immunohistochemistry 1+ and 2+ tissue expression with negative ISH assay), switched the scientific focus on this newly defined subset of breast cancer [28]. Here, ERBB2 is linked to breast cancer.